nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC18A2—Parkinson's disease	0.295	0.381	CbGaD
Amphetamine—MAOB—Parkinson's disease	0.202	0.261	CbGaD
Amphetamine—SLC6A3—Parkinson's disease	0.122	0.158	CbGaD
Amphetamine—DRD2—Parkinson's disease	0.0909	0.117	CbGaD
Amphetamine—CYP2D6—Parkinson's disease	0.0643	0.083	CbGaD
Amphetamine—CARTPT—telencephalic ventricle—Parkinson's disease	0.00845	0.0943	CbGeAlD
Amphetamine—SLC18A2—adrenal medulla—Parkinson's disease	0.0072	0.0803	CbGeAlD
Amphetamine—CARTPT—nerve—Parkinson's disease	0.00533	0.0595	CbGeAlD
Amphetamine—CARTPT—hindbrain—Parkinson's disease	0.00399	0.0445	CbGeAlD
Amphetamine—SLC6A2—locus ceruleus—Parkinson's disease	0.0037	0.0412	CbGeAlD
Amphetamine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00292	0.0326	CbGeAlD
Amphetamine—SLC18A2—telencephalic ventricle—Parkinson's disease	0.00287	0.0321	CbGeAlD
Amphetamine—CARTPT—brainstem—Parkinson's disease	0.00229	0.0255	CbGeAlD
Amphetamine—CARTPT—forebrain—Parkinson's disease	0.00221	0.0246	CbGeAlD
Amphetamine—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00217	0.0242	CbGeAlD
Amphetamine—SLC6A2—autonomic nervous system—Parkinson's disease	0.00196	0.0219	CbGeAlD
Amphetamine—DRD2—telencephalic ventricle—Parkinson's disease	0.0016	0.0178	CbGeAlD
Amphetamine—CARTPT—medulla oblongata—Parkinson's disease	0.00159	0.0178	CbGeAlD
Amphetamine—CARTPT—spinal cord—Parkinson's disease	0.00142	0.0159	CbGeAlD
Amphetamine—SLC6A3—nerve—Parkinson's disease	0.00137	0.0153	CbGeAlD
Amphetamine—CARTPT—head—Parkinson's disease	0.00126	0.0141	CbGeAlD
Amphetamine—SLC22A3—tongue—Parkinson's disease	0.00126	0.0141	CbGeAlD
Amphetamine—TAAR1—nervous system—Parkinson's disease	0.0012	0.0134	CbGeAlD
Amphetamine—CARTPT—nervous system—Parkinson's disease	0.0012	0.0134	CbGeAlD
Amphetamine—MAOB—nerve—Parkinson's disease	0.00119	0.0133	CbGeAlD
Amphetamine—TAAR1—central nervous system—Parkinson's disease	0.00115	0.0129	CbGeAlD
Amphetamine—CARTPT—central nervous system—Parkinson's disease	0.00115	0.0129	CbGeAlD
Amphetamine—CARTPT—cerebellum—Parkinson's disease	0.00113	0.0126	CbGeAlD
Amphetamine—SLC6A2—nerve—Parkinson's disease	0.0011	0.0123	CbGeAlD
Amphetamine—SLC6A3—hindbrain—Parkinson's disease	0.00103	0.0114	CbGeAlD
Amphetamine—DRD2—nerve—Parkinson's disease	0.00101	0.0112	CbGeAlD
Amphetamine—SLC6A4—hindbrain—Parkinson's disease	0.00094	0.0105	CbGeAlD
Amphetamine—CARTPT—brain—Parkinson's disease	0.000916	0.0102	CbGeAlD
Amphetamine—MAOB—hindbrain—Parkinson's disease	0.000894	0.00997	CbGeAlD
Amphetamine—SLC18A2—brainstem—Parkinson's disease	0.000777	0.00867	CbGeAlD
Amphetamine—DRD2—hindbrain—Parkinson's disease	0.000754	0.00841	CbGeAlD
Amphetamine—SLC18A2—forebrain—Parkinson's disease	0.00075	0.00837	CbGeAlD
Amphetamine—SLC22A3—embryo—Parkinson's disease	0.000604	0.00674	CbGeAlD
Amphetamine—SLC6A3—brainstem—Parkinson's disease	0.000588	0.00656	CbGeAlD
Amphetamine—SLC6A3—forebrain—Parkinson's disease	0.000567	0.00633	CbGeAlD
Amphetamine—MAOB—embryo—Parkinson's disease	0.000559	0.00624	CbGeAlD
Amphetamine—SLC18A2—medulla oblongata—Parkinson's disease	0.000542	0.00605	CbGeAlD
Amphetamine—SLC6A4—brainstem—Parkinson's disease	0.000539	0.00601	CbGeAlD
Amphetamine—SLC6A4—forebrain—Parkinson's disease	0.00052	0.0058	CbGeAlD
Amphetamine—MAOB—brainstem—Parkinson's disease	0.000512	0.00572	CbGeAlD
Amphetamine—SLC18A2—midbrain—Parkinson's disease	0.000495	0.00553	CbGeAlD
Amphetamine—MAOB—forebrain—Parkinson's disease	0.000494	0.00552	CbGeAlD
Amphetamine—Lisdexamfetamine—SLC18A2—Parkinson's disease	0.000475	0.0707	CrCbGaD
Amphetamine—SLC6A2—brainstem—Parkinson's disease	0.000474	0.00529	CbGeAlD
Amphetamine—SLC6A2—forebrain—Parkinson's disease	0.000458	0.00511	CbGeAlD
Amphetamine—CYP2D6—hindbrain—Parkinson's disease	0.000453	0.00506	CbGeAlD
Amphetamine—DRD2—brainstem—Parkinson's disease	0.000432	0.00482	CbGeAlD
Amphetamine—SLC18A2—head—Parkinson's disease	0.00043	0.00479	CbGeAlD
Amphetamine—MAOB—cardiovascular system—Parkinson's disease	0.000418	0.00466	CbGeAlD
Amphetamine—DRD2—forebrain—Parkinson's disease	0.000417	0.00465	CbGeAlD
Amphetamine—SLC18A2—nervous system—Parkinson's disease	0.000407	0.00454	CbGeAlD
Amphetamine—SLC18A2—central nervous system—Parkinson's disease	0.000392	0.00437	CbGeAlD
Amphetamine—SLC18A2—cerebellum—Parkinson's disease	0.000383	0.00428	CbGeAlD
Amphetamine—Pargyline—MAOB—Parkinson's disease	0.000378	0.0562	CrCbGaD
Amphetamine—SLC6A3—midbrain—Parkinson's disease	0.000375	0.00418	CbGeAlD
Amphetamine—Ephedrine—SLC18A2—Parkinson's disease	0.000372	0.0553	CrCbGaD
Amphetamine—SLC6A3—spinal cord—Parkinson's disease	0.000366	0.00408	CbGeAlD
Amphetamine—MAOB—medulla oblongata—Parkinson's disease	0.000357	0.00399	CbGeAlD
Amphetamine—SLC6A4—midbrain—Parkinson's disease	0.000343	0.00383	CbGeAlD
Amphetamine—CYP2A6—cerebellum—Parkinson's disease	0.000342	0.00382	CbGeAlD
Amphetamine—SLC6A4—spinal cord—Parkinson's disease	0.000335	0.00374	CbGeAlD
Amphetamine—SLC6A2—medulla oblongata—Parkinson's disease	0.000331	0.00369	CbGeAlD
Amphetamine—MAOB—midbrain—Parkinson's disease	0.000326	0.00364	CbGeAlD
Amphetamine—SLC6A3—head—Parkinson's disease	0.000325	0.00363	CbGeAlD
Amphetamine—MAOB—spinal cord—Parkinson's disease	0.000318	0.00355	CbGeAlD
Amphetamine—SLC18A2—brain—Parkinson's disease	0.000311	0.00347	CbGeAlD
Amphetamine—SLC6A3—nervous system—Parkinson's disease	0.000308	0.00344	CbGeAlD
Amphetamine—SLC22A3—head—Parkinson's disease	0.000306	0.00341	CbGeAlD
Amphetamine—SLC6A4—head—Parkinson's disease	0.000298	0.00332	CbGeAlD
Amphetamine—SLC6A3—central nervous system—Parkinson's disease	0.000297	0.00331	CbGeAlD
Amphetamine—SLC22A3—nervous system—Parkinson's disease	0.00029	0.00324	CbGeAlD
Amphetamine—SLC6A3—cerebellum—Parkinson's disease	0.00029	0.00323	CbGeAlD
Amphetamine—Dextroamphetamine—SLC18A2—Parkinson's disease	0.000284	0.0422	CrCbGaD
Amphetamine—MAOB—head—Parkinson's disease	0.000283	0.00316	CbGeAlD
Amphetamine—SLC6A4—nervous system—Parkinson's disease	0.000282	0.00315	CbGeAlD
Amphetamine—SLC22A5—medulla oblongata—Parkinson's disease	0.000281	0.00313	CbGeAlD
Amphetamine—SLC22A3—central nervous system—Parkinson's disease	0.000279	0.00312	CbGeAlD
Amphetamine—CYP2A6—brain—Parkinson's disease	0.000278	0.0031	CbGeAlD
Amphetamine—DRD2—midbrain—Parkinson's disease	0.000275	0.00307	CbGeAlD
Amphetamine—SLC6A4—central nervous system—Parkinson's disease	0.000272	0.00303	CbGeAlD
Amphetamine—MAOB—nervous system—Parkinson's disease	0.000268	0.00299	CbGeAlD
Amphetamine—L-Phenylalanine—TH—Parkinson's disease	0.000268	0.0398	CrCbGaD
Amphetamine—Pargyline—MAOA—Parkinson's disease	0.000265	0.0394	CrCbGaD
Amphetamine—SLC6A2—head—Parkinson's disease	0.000262	0.00292	CbGeAlD
Amphetamine—Diethylpropion—SLC6A3—Parkinson's disease	0.00026	0.0387	CrCbGaD
Amphetamine—CYP2D6—brainstem—Parkinson's disease	0.00026	0.0029	CbGeAlD
Amphetamine—MAOB—central nervous system—Parkinson's disease	0.000258	0.00288	CbGeAlD
Amphetamine—SLC22A5—midbrain—Parkinson's disease	0.000257	0.00286	CbGeAlD
Amphetamine—MAOB—cerebellum—Parkinson's disease	0.000253	0.00282	CbGeAlD
Amphetamine—CYP2D6—forebrain—Parkinson's disease	0.000251	0.0028	CbGeAlD
Amphetamine—SLC22A5—spinal cord—Parkinson's disease	0.00025	0.00279	CbGeAlD
Amphetamine—SLC6A2—nervous system—Parkinson's disease	0.000249	0.00277	CbGeAlD
Amphetamine—Tranylcypromine—MAOB—Parkinson's disease	0.000243	0.0362	CrCbGaD
Amphetamine—SLC6A2—central nervous system—Parkinson's disease	0.000239	0.00267	CbGeAlD
Amphetamine—DRD2—head—Parkinson's disease	0.000239	0.00267	CbGeAlD
Amphetamine—SLC6A3—brain—Parkinson's disease	0.000235	0.00263	CbGeAlD
Amphetamine—DRD2—nervous system—Parkinson's disease	0.000226	0.00253	CbGeAlD
Amphetamine—SLC22A3—brain—Parkinson's disease	0.000222	0.00247	CbGeAlD
Amphetamine—DRD2—central nervous system—Parkinson's disease	0.000218	0.00243	CbGeAlD
Amphetamine—SLC6A4—brain—Parkinson's disease	0.000216	0.00241	CbGeAlD
Amphetamine—DRD2—cerebellum—Parkinson's disease	0.000213	0.00238	CbGeAlD
Amphetamine—Methamphetamine—SLC18A2—Parkinson's disease	0.000212	0.0315	CrCbGaD
Amphetamine—Benzphetamine—SLC18A2—Parkinson's disease	0.00021	0.0312	CrCbGaD
Amphetamine—MAOB—brain—Parkinson's disease	0.000205	0.00229	CbGeAlD
Amphetamine—Phentermine—MAOB—Parkinson's disease	0.000204	0.0303	CrCbGaD
Amphetamine—SLC22A5—cerebellum—Parkinson's disease	0.000198	0.00221	CbGeAlD
Amphetamine—Lisdexamfetamine—SLC6A3—Parkinson's disease	0.000197	0.0293	CrCbGaD
Amphetamine—SLC6A2—brain—Parkinson's disease	0.00019	0.00212	CbGeAlD
Amphetamine—Selegiline—MAOB—Parkinson's disease	0.000189	0.0281	CrCbGaD
Amphetamine—DRD2—brain—Parkinson's disease	0.000173	0.00193	CbGeAlD
Amphetamine—Tranylcypromine—MAOA—Parkinson's disease	0.000171	0.0254	CrCbGaD
Amphetamine—Phenelzine—MAOB—Parkinson's disease	0.000166	0.0247	CrCbGaD
Amphetamine—SLC22A5—brain—Parkinson's disease	0.000161	0.0018	CbGeAlD
Amphetamine—Phenylpropanolamine—MAOA—Parkinson's disease	0.00016	0.0239	CrCbGaD
Amphetamine—Phenylpropanolamine—DRD1—Parkinson's disease	0.000146	0.0217	CrCbGaD
Amphetamine—Methamphetamine—MAOB—Parkinson's disease	0.000145	0.0216	CrCbGaD
Amphetamine—CYP2D6—head—Parkinson's disease	0.000144	0.0016	CbGeAlD
Amphetamine—Phentermine—MAOA—Parkinson's disease	0.000143	0.0213	CrCbGaD
Amphetamine—Phenylpropanolamine—SLC6A3—Parkinson's disease	0.000138	0.0206	CrCbGaD
Amphetamine—CYP2D6—nervous system—Parkinson's disease	0.000136	0.00152	CbGeAlD
Amphetamine—Pseudoephedrine—MAOA—Parkinson's disease	0.000136	0.0202	CrCbGaD
Amphetamine—Selegiline—MAOA—Parkinson's disease	0.000132	0.0197	CrCbGaD
Amphetamine—CYP2D6—central nervous system—Parkinson's disease	0.000131	0.00146	CbGeAlD
Amphetamine—CYP2D6—cerebellum—Parkinson's disease	0.000128	0.00143	CbGeAlD
Amphetamine—Phentermine—SLC6A3—Parkinson's disease	0.000123	0.0183	CrCbGaD
Amphetamine—Dextroamphetamine—SLC6A3—Parkinson's disease	0.000118	0.0175	CrCbGaD
Amphetamine—Pseudoephedrine—SLC6A3—Parkinson's disease	0.000117	0.0174	CrCbGaD
Amphetamine—Phenelzine—MAOA—Parkinson's disease	0.000117	0.0173	CrCbGaD
Amphetamine—Pseudoephedrine—TNF—Parkinson's disease	0.000109	0.0162	CrCbGaD
Amphetamine—Tranylcypromine—CYP2E1—Parkinson's disease	0.000105	0.0157	CrCbGaD
Amphetamine—CYP2D6—brain—Parkinson's disease	0.000104	0.00116	CbGeAlD
Amphetamine—Methamphetamine—MAOA—Parkinson's disease	0.000102	0.0152	CrCbGaD
Amphetamine—Phenformin—CYP2D6—Parkinson's disease	9.48e-05	0.0141	CrCbGaD
Amphetamine—Methamphetamine—SLC6A3—Parkinson's disease	8.79e-05	0.0131	CrCbGaD
Amphetamine—Benzphetamine—SLC6A3—Parkinson's disease	8.72e-05	0.013	CrCbGaD
Amphetamine—Benzyl alcohol—CYP2E1—Parkinson's disease	8.51e-05	0.0127	CrCbGaD
Amphetamine—Selegiline—CYP2E1—Parkinson's disease	8.17e-05	0.0121	CrCbGaD
Amphetamine—Tranylcypromine—CYP2D6—Parkinson's disease	7.73e-05	0.0115	CrCbGaD
Amphetamine—Phenelzine—CYP2E1—Parkinson's disease	7.2e-05	0.0107	CrCbGaD
Amphetamine—Phentermine—CYP2D6—Parkinson's disease	6.48e-05	0.00964	CrCbGaD
Amphetamine—Benzyl alcohol—CYP2D6—Parkinson's disease	6.25e-05	0.00929	CrCbGaD
Amphetamine—Dextroamphetamine—CYP2D6—Parkinson's disease	6.18e-05	0.00919	CrCbGaD
Amphetamine—Pseudoephedrine—CYP2D6—Parkinson's disease	6.14e-05	0.00914	CrCbGaD
Amphetamine—Selegiline—CYP2D6—Parkinson's disease	6e-05	0.00892	CrCbGaD
Amphetamine—Nateglinide—CYP2D6—Parkinson's disease	5.36e-05	0.00797	CrCbGaD
Amphetamine—Methamphetamine—CYP2D6—Parkinson's disease	4.62e-05	0.00687	CrCbGaD
Amphetamine—Selegiline—ABCB1—Parkinson's disease	4.28e-05	0.00637	CrCbGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	4.26e-05	0.00033	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—GSTM1—Parkinson's disease	4.25e-05	0.000329	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PDYN—Parkinson's disease	4.2e-05	0.000325	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—HTR2A—Parkinson's disease	4.14e-05	0.00032	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	4.13e-05	0.00032	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	4.11e-05	0.000319	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DGKQ—Parkinson's disease	4.03e-05	0.000312	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	4.01e-05	0.000311	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—INSR—Parkinson's disease	3.98e-05	0.000309	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—FBP1—Parkinson's disease	3.97e-05	0.000307	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—DBH—Parkinson's disease	3.97e-05	0.000307	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GBA—Parkinson's disease	3.97e-05	0.000307	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—GRM5—Parkinson's disease	3.9e-05	0.000302	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.85e-05	0.000298	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	3.79e-05	0.000294	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CP—Parkinson's disease	3.79e-05	0.000293	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	3.78e-05	0.000293	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	3.78e-05	0.000293	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—COMT—Parkinson's disease	3.78e-05	0.000293	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FGB—Parkinson's disease	3.76e-05	0.000292	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HTR2A—Parkinson's disease	3.76e-05	0.000291	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—MAOA—Parkinson's disease	3.75e-05	0.000291	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR1A—Parkinson's disease	3.74e-05	0.00029	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	3.73e-05	0.000289	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	3.73e-05	0.000289	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TAC1—Parkinson's disease	3.69e-05	0.000286	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GPR37—Parkinson's disease	3.66e-05	0.000283	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DGKQ—Parkinson's disease	3.66e-05	0.000283	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	3.65e-05	0.000283	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	3.64e-05	0.000282	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD1—Parkinson's disease	3.62e-05	0.00028	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	3.54e-05	0.000274	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD3—Parkinson's disease	3.5e-05	0.000271	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	3.47e-05	0.000269	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	3.46e-05	0.000268	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—DDC—Parkinson's disease	3.44e-05	0.000267	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CP—Parkinson's disease	3.35e-05	0.00026	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.35e-05	0.000259	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PPP1R1B—Parkinson's disease	3.34e-05	0.000259	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.33e-05	0.000258	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ADORA2A—Parkinson's disease	3.32e-05	0.000257	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.32e-05	0.000257	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ADRBK1—Parkinson's disease	3.27e-05	0.000253	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTA4—Parkinson's disease	3.25e-05	0.000252	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	3.21e-05	0.000249	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	3.2e-05	0.000248	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD2—Parkinson's disease	3.17e-05	0.000245	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR7—Parkinson's disease	3.17e-05	0.000245	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP2E1—Parkinson's disease	3.15e-05	0.000244	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP2E1—Parkinson's disease	3.1e-05	0.00024	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GRK5—Parkinson's disease	3.05e-05	0.000236	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ND3—Parkinson's disease	3.01e-05	0.000234	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MCCC1—Parkinson's disease	3.01e-05	0.000234	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PLA2G6—Parkinson's disease	2.93e-05	0.000227	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—DDC—Parkinson's disease	2.91e-05	0.000226	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	2.89e-05	0.000224	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	2.88e-05	0.000223	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR1A—Parkinson's disease	2.88e-05	0.000223	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—MAPK8—Parkinson's disease	2.84e-05	0.00022	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—TAC1—Parkinson's disease	2.84e-05	0.00022	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TALDO1—Parkinson's disease	2.83e-05	0.00022	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—OMD—Parkinson's disease	2.83e-05	0.00022	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD1—Parkinson's disease	2.78e-05	0.000216	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	2.78e-05	0.000215	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GRK5—Parkinson's disease	2.77e-05	0.000215	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	2.77e-05	0.000214	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTA4—Parkinson's disease	2.75e-05	0.000213	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—Parkinson's disease	2.75e-05	0.000213	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GRM4—Parkinson's disease	2.74e-05	0.000212	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	2.7e-05	0.000209	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD3—Parkinson's disease	2.69e-05	0.000209	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NDUFB11—Parkinson's disease	2.69e-05	0.000208	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF2—Parkinson's disease	2.65e-05	0.000206	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	2.62e-05	0.000203	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—COMT—Parkinson's disease	2.61e-05	0.000202	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VPS35—Parkinson's disease	2.61e-05	0.000202	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTP1—Parkinson's disease	2.59e-05	0.000201	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PENK—Parkinson's disease	2.59e-05	0.000201	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—CYCS—Parkinson's disease	2.59e-05	0.000201	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—MAOA—Parkinson's disease	2.59e-05	0.000201	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—COMT—Parkinson's disease	2.57e-05	0.000199	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1R—Parkinson's disease	2.57e-05	0.000199	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GCH1—Parkinson's disease	2.56e-05	0.000199	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	2.56e-05	0.000198	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTP1—Parkinson's disease	2.56e-05	0.000198	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EDN1—Parkinson's disease	2.54e-05	0.000196	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GRM4—Parkinson's disease	2.49e-05	0.000193	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PLA2G6—Parkinson's disease	2.48e-05	0.000192	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MAOB—Parkinson's disease	2.45e-05	0.00019	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR7—Parkinson's disease	2.44e-05	0.000189	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTM1—Parkinson's disease	2.38e-05	0.000185	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PDYN—Parkinson's disease	2.37e-05	0.000184	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PENK—Parkinson's disease	2.36e-05	0.000183	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTM1—Parkinson's disease	2.35e-05	0.000182	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NGF—Parkinson's disease	2.33e-05	0.000181	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CYCS—Parkinson's disease	2.29e-05	0.000178	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GBA—Parkinson's disease	2.28e-05	0.000177	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—FBP1—Parkinson's disease	2.28e-05	0.000177	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—DBH—Parkinson's disease	2.28e-05	0.000177	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	2.25e-05	0.000174	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	2.24e-05	0.000174	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—Parkinson's disease	2.22e-05	0.000172	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR2A—Parkinson's disease	2.22e-05	0.000172	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GRM5—Parkinson's disease	2.21e-05	0.000171	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	2.16e-05	0.000167	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DGKQ—Parkinson's disease	2.16e-05	0.000167	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GPR37—Parkinson's disease	2.16e-05	0.000167	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PDYN—Parkinson's disease	2.16e-05	0.000167	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP2D6—Parkinson's disease	2.15e-05	0.000167	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CTGF—Parkinson's disease	2.11e-05	0.000164	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APOE—Parkinson's disease	2.06e-05	0.00016	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GRM5—Parkinson's disease	2e-05	0.000155	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	1.99e-05	0.000155	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PPP1R1B—Parkinson's disease	1.98e-05	0.000153	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP2E1—Parkinson's disease	1.97e-05	0.000153	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—EDN1—Parkinson's disease	1.95e-05	0.000151	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NQO1—Parkinson's disease	1.95e-05	0.000151	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TH—Parkinson's disease	1.92e-05	0.000149	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	1.91e-05	0.000148	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADORA2A—Parkinson's disease	1.88e-05	0.000145	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYCS—Parkinson's disease	1.84e-05	0.000143	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP2D6—Parkinson's disease	1.82e-05	0.000141	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—Parkinson's disease	1.81e-05	0.00014	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CTGF—Parkinson's disease	1.79e-05	0.000139	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—INS—Parkinson's disease	1.76e-05	0.000136	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—MAPK8—Parkinson's disease	1.74e-05	0.000134	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RIT2—Parkinson's disease	1.73e-05	0.000134	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR2A—Parkinson's disease	1.71e-05	0.000132	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADORA2A—Parkinson's disease	1.7e-05	0.000132	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ND3—Parkinson's disease	1.69e-05	0.000131	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MCCC1—Parkinson's disease	1.69e-05	0.000131	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—DDC—Parkinson's disease	1.68e-05	0.00013	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP2E1—Parkinson's disease	1.67e-05	0.000129	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NQO1—Parkinson's disease	1.65e-05	0.000128	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRK5—Parkinson's disease	1.64e-05	0.000127	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—COMT—Parkinson's disease	1.63e-05	0.000126	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR1A—Parkinson's disease	1.63e-05	0.000126	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTP1—Parkinson's disease	1.62e-05	0.000126	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TH—Parkinson's disease	1.62e-05	0.000126	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MAOA—Parkinson's disease	1.62e-05	0.000126	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TAC1—Parkinson's disease	1.6e-05	0.000124	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HMOX1—Parkinson's disease	1.6e-05	0.000124	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TALDO1—Parkinson's disease	1.59e-05	0.000123	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—OMD—Parkinson's disease	1.59e-05	0.000123	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTA4—Parkinson's disease	1.58e-05	0.000123	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD1—Parkinson's disease	1.57e-05	0.000122	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYCS—Parkinson's disease	1.56e-05	0.000121	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ABCB1—Parkinson's disease	1.54e-05	0.000119	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD3—Parkinson's disease	1.52e-05	0.000118	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	1.51e-05	0.000117	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTM1—Parkinson's disease	1.49e-05	0.000116	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR1A—Parkinson's disease	1.48e-05	0.000115	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRM4—Parkinson's disease	1.47e-05	0.000114	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TAC1—Parkinson's disease	1.46e-05	0.000113	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GCH1—Parkinson's disease	1.44e-05	0.000111	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GPX1—Parkinson's disease	1.43e-05	0.000111	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD1—Parkinson's disease	1.43e-05	0.000111	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLA2G6—Parkinson's disease	1.43e-05	0.00011	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADRBK1—Parkinson's disease	1.42e-05	0.00011	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MAOB—Parkinson's disease	1.41e-05	0.000109	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PENK—Parkinson's disease	1.39e-05	0.000108	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAG—Parkinson's disease	1.39e-05	0.000108	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD3—Parkinson's disease	1.38e-05	0.000107	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—COMT—Parkinson's disease	1.38e-05	0.000107	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR7—Parkinson's disease	1.38e-05	0.000107	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTP1—Parkinson's disease	1.37e-05	0.000106	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MAOA—Parkinson's disease	1.37e-05	0.000106	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HMOX1—Parkinson's disease	1.36e-05	0.000105	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MTHFR—Parkinson's disease	1.32e-05	0.000102	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP3—Parkinson's disease	1.31e-05	0.000102	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—Parkinson's disease	1.3e-05	0.000101	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCB1—Parkinson's disease	1.3e-05	0.000101	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADRBK1—Parkinson's disease	1.29e-05	0.0001	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—DBH—Parkinson's disease	1.28e-05	9.93e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FBP1—Parkinson's disease	1.28e-05	9.93e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GBA—Parkinson's disease	1.28e-05	9.93e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDYN—Parkinson's disease	1.27e-05	9.86e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTM1—Parkinson's disease	1.26e-05	9.78e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR7—Parkinson's disease	1.25e-05	9.69e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOE—Parkinson's disease	1.23e-05	9.51e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GPX1—Parkinson's disease	1.21e-05	9.37e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK8—Parkinson's disease	1.21e-05	9.34e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GFAP—Parkinson's disease	1.2e-05	9.27e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRM5—Parkinson's disease	1.18e-05	9.17e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—Parkinson's disease	1.12e-05	8.65e-05	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—Parkinson's disease	1.11e-05	8.59e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—EDN1—Parkinson's disease	1.1e-05	8.54e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—INS—Parkinson's disease	1.05e-05	8.13e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2D6—Parkinson's disease	1.05e-05	8.13e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOE—Parkinson's disease	1.04e-05	8.05e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGF20—Parkinson's disease	1.04e-05	8.04e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CTGF—Parkinson's disease	1.03e-05	7.98e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADORA2A—Parkinson's disease	1.01e-05	7.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDN1—Parkinson's disease	1e-05	7.76e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR2A—Parkinson's disease	9.64e-06	7.47e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2E1—Parkinson's disease	9.6e-06	7.43e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NQO1—Parkinson's disease	9.49e-06	7.35e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—DDC—Parkinson's disease	9.4e-06	7.29e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TH—Parkinson's disease	9.35e-06	7.24e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INSR—Parkinson's disease	9.29e-06	7.19e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYCS—Parkinson's disease	8.98e-06	6.95e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	8.88e-06	6.88e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—INS—Parkinson's disease	8.88e-06	6.88e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGB—Parkinson's disease	8.78e-06	6.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR2A—Parkinson's disease	8.76e-06	6.78e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR1A—Parkinson's disease	8.73e-06	6.76e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TAC1—Parkinson's disease	8.6e-06	6.66e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD1—Parkinson's disease	8.43e-06	6.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD3—Parkinson's disease	8.17e-06	6.33e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	8e-06	6.19e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—COMT—Parkinson's disease	7.95e-06	6.16e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MAOB—Parkinson's disease	7.92e-06	6.13e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTP1—Parkinson's disease	7.91e-06	6.13e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MAOA—Parkinson's disease	7.89e-06	6.12e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HMOX1—Parkinson's disease	7.8e-06	6.05e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—Parkinson's disease	7.7e-06	5.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRBK1—Parkinson's disease	7.63e-06	5.91e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCB1—Parkinson's disease	7.49e-06	5.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR7—Parkinson's disease	7.39e-06	5.72e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—Parkinson's disease	7.27e-06	5.63e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GPX1—Parkinson's disease	6.96e-06	5.39e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—Parkinson's disease	6.43e-06	4.98e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF2—Parkinson's disease	6.19e-06	4.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1R—Parkinson's disease	5.98e-06	4.64e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOE—Parkinson's disease	5.98e-06	4.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDN1—Parkinson's disease	5.91e-06	4.58e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CTGF—Parkinson's disease	5.77e-06	4.47e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NGF—Parkinson's disease	5.43e-06	4.21e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	5.38e-06	4.17e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NQO1—Parkinson's disease	5.32e-06	4.12e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TH—Parkinson's disease	5.24e-06	4.06e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR2A—Parkinson's disease	5.17e-06	4.01e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—INS—Parkinson's disease	5.11e-06	3.96e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYCS—Parkinson's disease	5.03e-06	3.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOE—Parkinson's disease	4.81e-06	3.73e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—COMT—Parkinson's disease	4.46e-06	3.45e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	4.44e-06	3.44e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MAOA—Parkinson's disease	4.43e-06	3.43e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	4.38e-06	3.39e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	4.2e-06	3.25e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INS—Parkinson's disease	4.11e-06	3.18e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	4.08e-06	3.16e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPX1—Parkinson's disease	3.91e-06	3.03e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	3.6e-06	2.79e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOE—Parkinson's disease	3.36e-06	2.6e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—Parkinson's disease	3.06e-06	2.37e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—Parkinson's disease	3.04e-06	2.35e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—INS—Parkinson's disease	2.87e-06	2.22e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK8—Parkinson's disease	2.81e-06	2.18e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—Parkinson's disease	1.8e-06	1.39e-05	CbGpPWpGaD
